Angiographic, procedural characteristics and discharge therapy of study population
| Variables | Group A (10/10) (n=95) | Group B (10/5) (n=98) | All (n=193) | p Value |
|---|---|---|---|---|
| Angiographic characteristics | ||||
| Multivessel coronary disease | 61 (64.2) | 57 (58.2) | 118 (61.1) | 0.389 |
| Three-vessel coronary disease | 30 (31.6) | 25 (25.5) | 55 (28.5) | 0.350 |
| Left main disease | 14 (14.7) | 15 (15.3) | 29 (15.0) | 0.912 |
| Procedural characteristics | ||||
| Number of treated vessels | 1.5±0.7 | 1.5±0.7 | 1.5±0.7 | 0.798 |
| Total stent length, mm | 49.0±35.7 | 41.4±29.7 | 45.2±33.0 | 0.107 |
| Stent length per culprit vessel, mm | 33.4±23.6 | 28.7±18.0 | 31.0±21.0 | 0.118 |
| Number of stents per patient | 2.3±1.3 | 2.0±1.2 | 2.2±1.3 | 0.145 |
| Number of stents per culprit vessel | 1.6±0.8 | 1.4±0.7 | 1.5±0.8 | 0.179 |
| Multivessel PCI | 39 (41.1) | 38 (38.8) | 77 (39.9) | 0.747 |
| DES | 95 (100) | 98 (100) | 193 (100) | – |
| Second-generation DES | 72 (75.8) | 70 (71.4) | 142 (73.5) | 0.492 |
| Everolimus Eluting Stent (Xience) | 65 (90.3) | 59 (85.5) | 124 (87.9) | 0.233 |
| Everolimus Eluting Platinum Chromium Stent (Promus Element Plus) | 6 (8.3) | 9 (13.0) | 15 (10.6) | 0.365 |
| Zotarolimus Eluting Stent (Resolute Integrity) | 1 (1.4) | 2 (2.9) | 3 (2.1) | 0.535 |
| Third-generation DES | 23 (24.2) | 28 (28.6) | 51 (26.4) | 0.492 |
| Biodegradable polymer biolimus-eluting stent (Nobori) | 10 (43.5) | 9 (32.1) | 19 (37.3) | 0.405 |
| BioFreedom Polymer-Free (Cre8) | 13 (56.5) | 19 (67.9) | 32 (62.7) | 0.405 |
| GP inhibitors IIb/IIIa | 18 (18.9) | 23(23.5) | 41 (21%) | 0.442 |
| Discharge therapy | ||||
| Aspirin | 95 (100) | 98 (100) | 193 (100) | – |
| Statins | 92 (96.8) | 92 (93.9) | 184 (95.3) | 0.329 |
| ACE inhibitors or ARBs | 67 (70.5) | 78 (79.6) | 145 (75.1) | 0.145 |
| β-blockers | 70 (73.7) | 60 (61.2) | 130 (67.4) | 0.065 |
| Proton pump inhibitors | 78 (82.1) | 71 (72.4) | 149 (77.2) | 0.110 |
| Hospital length of stay, day | 3.4±2.0 | 3.7±5.9 | 3.5±4.4 | 0.544 |
Values are expressed as mean±SD or n (%).
ARBs, angiotensin receptor blockers; DES, drug-eluting stent; GP, glycoprotein; PCI, percutaneous coronary intervention.